This advertorial is sponsored by Revvity. Antibody Drug Conjugates (ADCs) represent one of the most rapidly expanding oncology therapeutic categories. Hundreds of candidates are undergoing active clinical development, with about two hundred companies engaged in ADC development1. Recent regulatory adjustments within the pharmaceutical industry in the US have begun to influence drug developers’ research strategies […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!